Literature DB >> 8060555

Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients.

A Vuffray, C Durussel, P Boerlin, F Boerlin-Petzold, J Bille, M P Glauser, J P Chave.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8060555     DOI： 10.1097/00002030-199405000-00023

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  17 in total

1.  Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance.

Authors:  Taiga Miyazaki; Yoshitsugu Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Shunichi Miyakoshi; John E Bennett; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 2.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 3.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

4.  Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting.

Authors:  P Boerlin; F Boerlin-Petzold; J Goudet; C Durussel; J L Pagani; J P Chave; J Bille
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 5.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

6.  Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole.

Authors:  T Wu; K Wright; S F Hurst; C J Morrison
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 7.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

8.  Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection.

Authors:  S W Redding; M A Pfaller; S A Messer; J A Smith; J Prows; L L Bradley; A W Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

9.  Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users.

Authors:  P Boerlin; F Boerlin-Petzold; C Durussel; M Addo; J L Pagani; J P Chave; J Bille
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

Review 10.  Fungal infections: a growing threat.

Authors:  D M Dixon; M M McNeil; M L Cohen; B G Gellin; J R La Montagne
Journal:  Public Health Rep       Date:  1996 May-Jun       Impact factor: 2.792
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.